SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 51,884 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 51,884 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $19.46, for a total value of $1,009,662.64. Following the sale, the chief executive officer directly owned 321,386 shares in the company, valued at approximately $6,254,171.56. This represents a 13.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.

SiBone Stock Performance

NASDAQ SIBN opened at $19.96 on Friday. The firm has a market cap of $885.23 million, a price-to-earnings ratio of -58.71 and a beta of 0.66. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $17.49 and a 200-day moving average price of $15.33. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The company had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. As a group, equities research analysts predict that SiBone will post -0.4 EPS for the current fiscal year.

Institutional Trading of SiBone

Several hedge funds have recently modified their holdings of SIBN. First Light Asset Management LLC grew its holdings in shares of SiBone by 6.4% in the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after purchasing an additional 320,286 shares in the last quarter. Vanguard Group Inc. raised its stake in SiBone by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock valued at $49,331,000 after purchasing an additional 11,566 shares in the last quarter. Granahan Investment Management LLC raised its stake in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after purchasing an additional 858,942 shares in the last quarter. Nuveen LLC lifted its position in SiBone by 5.1% during the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after purchasing an additional 69,229 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its position in SiBone by 17.1% during the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock valued at $23,664,000 after purchasing an additional 175,000 shares during the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SIBN shares. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. TD Cowen raised their target price on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Truist Financial reiterated a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. Finally, UBS Group boosted their price target on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.